ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

RESPIRATORY

THE POWER OF PULMONARY: ADVANCES IN INHALED DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS

Jonathan Mulpas discusses how advanced inhaled delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential.

SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?

Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.

TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?

Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Dr Heather Jameson

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.

DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES

Dr Clair Brooks

Copley Scientific

DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES

Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.

MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION

Catalent Pharma Solutions

MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION

Alan Watts, Yusuf Ahmed and Gabriela Dujovny discuss manufacturing methods for inhalation powders and explain how moisture protection is an essential consideration throughout the manufacturing process.

NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING

NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING

Sophie Conte and Alain Regard, describe Nemera’s journey in nose-to-brain device development, highlighting the evaluation tools, methods and usability testing developed in-house to steer innovative device design and engineering.

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.

REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH

Dr Carolina Dantas

Pulmotree Medical

REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH

Carolina Dantas, Ulf Krueger and Howard Burnett discuss the critical need for precision when delivering biologics to the lungs, how PULMOTREE’s Kolibri is able to achieve this using guided breathing, and how the use of realistic breathing profiles can improve outcomes and decrease risk with in vitro and in silico testing.

CONFERENCE PREVIEW: SMI.LONDON

CONFERENCE SHOWCASE

CONFERENCE PREVIEW: SMI.LONDON

Join colleagues from across the inhalation space at SMI.London 2025, the only conference dedicated to soft mist inhalers (SMIs) worldwide. The event will take place on Wednesday, June 25, 2025, at the Pullman London St Pancras, hosted by Merxin.

A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS

Dr Reza Abedian

A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS

Dr Reza Abedian, Marie Stockton and Bernd Zeiss consider the complexities and clinical unmet needs of intravitreal injections and discuss how Gerresheimer’s syringe technology can help overcome these challenges.

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

Zoë Davidson considers the impact of glaucoma on global health and the challenges presented by the increasing prevalence of this disease in the ageing global population, discussing how Novelia®, Nemera’s multidose eyedropper for preservative-free formulations, is well-positioned to address many of the challenges presented by glaucoma treatments, from ease of use to sustainability.

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

Joe Batley and Lorna Barron provide an overview of the latest cutting-edge ophthalmic delivery methods and discuss possible future developments.

A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE

Dr Anu Prabhathachandran

West Pharmaceutical Services

A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE

Anu Prabhathachandran, Menachem Peretz and Manali Potnis discuss the growing need for more effective delivery of ophthalmic therapeutics to meet the needs of the ageing population, including how delivery into the suprachoroidal space may present an appealing alternative to intravitreal injection. They introduce West Pharmaceutical Service’ Suprachoroidal Advanceable Microneedle Device, which offers several advantages for overcoming the challenges with suprachoroidal space.

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

Binbin Tian discusses antisense oligonucleotides and considers their potential as treatments for genetic and multifactorial ophthalmic diseases previously considered untreatable. The article considers how these therapies function as treatments, their current state of development, challenges in their delivery and the evolving regulatory landscape

INTRODUCING THE TERUMO INJECTION FILTER NEEDLE – A FIRST STEP OF THE INFINO™ DEVELOPMENT PROGRAMME

Terumo Medical Care Solutions

INTRODUCING THE TERUMO INJECTION FILTER NEEDLE – A FIRST STEP OF THE INFINO™ DEVELOPMENT PROGRAMME

Thomas Isaac considers the issues associated with injection to highly sensitive areas, such as the vitreous body, and the potential to optimise needle design and features to address these issues, discussing the key features of Terumo’s Injection Filter Needle, indicated for hypodermic and intravitreal injections within this context.

THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS

Dr Andreas Schneider

THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS

Andreas Schneider and Jakob Lange consider the SC administration of larger volumes of biopharmaceuticals in the pharma industry and summarise a recent study that reviews clinical-stage and approved IV and SC biopharmaceuticals to provide valuable guidance for new product development, as well as for marketing and commercialisation strategies in the rapidly evolving large-volume SC landscape.

CONTAINER SELECTION FOR A HIGHLY SENSITIVE DRUG PRODUCT: A SUCCESS STORY

Enrico Barichello

Stevanato Group

CONTAINER SELECTION FOR A HIGHLY SENSITIVE DRUG PRODUCT: A SUCCESS STORY

Enrico Barichello discusses Stevanato Group’s collaboration with a leading pharmaceutical company to identify a suitable container for a high-concentration monoclonal antibody. The partnership addressed key challenges and contributed to maintaining the drug’s stability and integrity throughout its lifecycle.

DRUG DELIVERY TRENDS FOR 2025

DRUG DELIVERY TRENDS FOR 2025

Tom Oakley and Alex Vasiev look back at how the trends anticipated for 2024 played out in reality and look forward to four major trends expected to influence the drug delivery industry in 2025.

EMPOWERING PHARMA WITH INNOVATIVE INFUSION TECHNOLOGIES AMID US POLICY CHANGES

EMPOWERING PHARMA WITH INNOVATIVE INFUSION TECHNOLOGIES AMID US POLICY CHANGES

Mindy Katz and Michael Ratigan outline the implications for pharmaceutical manufacturers of recent US policy changes – and highlight how Eitan Medical’s portfolio of infusion solutions can offer support.

510(k) CLEARED, USER-FILLED MICRODOSING DEVICE FOR OPHTHALMIC AND OTHER APPLICATIONS

PREFILLED SYRINGES

Dr Gautam Shetty

Congruence Medical Solutions

510(k) CLEARED, USER-FILLED MICRODOSING DEVICE FOR OPHTHALMIC AND OTHER APPLICATIONS

Gautam Shetty discusses unmet drug delivery needs in applications requiring accurate and precise microlitre-scale doses,going on to detail how the Congruence Medical’s recently cleared Microliter Dosing Syringe can bring the benefits of advanced syringe materials and performance to these applications.

TUB & NEST – PRECISION AND EFFICIENCY IN DRUG DELIVERY

PREFILLED SYRINGES

TUB & NEST – PRECISION AND EFFICIENCY IN DRUG DELIVERY

Ivana Thiesson and Jörg Sander applied marketing discuss the benefits of Fischer Söhne’s “Tub & Nest” format for packaging prefilled syringes, including design flexibility and precise cleanroom manufacturing.

UNLOCK VALUE: KEY COST DRIVERS IN SPRING AND STAMPING DESIGN

INDUSTRIALISATION

Rolando Abaroa Martinez

Baumann Medical

UNLOCK VALUE: KEY COST DRIVERS IN SPRING AND STAMPING DESIGN

Rolando Abaroa Martinez and David Pircher highlight how a metal parts supplier can help to optimise costs – not only for springs and stampings but also in later production stages of a medical device. With a focus on the design phase, they emphasise that not only the costs associated with the metal product but also the total costs can be managed effectively with the right support from experts.

THE ROLE OF METAL DEEP-DRAWN PARTS IN MEDICAL DEVICES FOR DRUG DELIVERY

INDUSTRIALISATION

Dennis Gossmann

STÜKEN Medical

THE ROLE OF METAL DEEP-DRAWN PARTS IN MEDICAL DEVICES FOR DRUG DELIVERY

Dennis Gossmann discusses the benefits of using deep-drawn metal components in drug delivery devices and how STÜKEN MEDICAL, as an established expert in this field, can be an ideal partner for manufacturing and supplying these parts.

HIGH-DOSE DRUG DELIVERY – HOW FAR CAN AUTOINJECTORS GO?

Dr Iain Simpson

Phillips Medisize

HIGH-DOSE DRUG DELIVERY – HOW FAR CAN AUTOINJECTORS GO?

Iain Simpson reviews the development of autoinjectors for self-injection and explains that, despite significant emerging trends for biologics, new developments in formulation and autoinjector technology may enable them to continue to be the dominant delivery device for these medications.

TESTING SYRINGES & INJECTION DEVICES: SOLUTIONS THAT BOOST EFFICIENCY

TESTING SYRINGES & INJECTION DEVICES: SOLUTIONS THAT BOOST EFFICIENCY

Peter Schmidt discusses ZwickRoell’s offerings in the arena of testing systems for injectable drug delivery systems, in particular highlighting the advantages of automation for providing reliable, reproducible results.

FROM PLATFORM TO PRODUCT: ACCELERATING TIME-TO-MARKET FOR PLATFORM TECHNOLOGIES

FROM PLATFORM TO PRODUCT: ACCELERATING TIME-TO-MARKET FOR PLATFORM TECHNOLOGIES

Fran Pencliffe explores the benefits of platform devices for parenteral delivery and outlines the challenges, risks and best practices when bringing a combination product to market in this way.

1
2
3
…
63
Next

See what ondrugdelivery's readers and contributors think

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Top